Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100
- 25 January 1993
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 98 (2) , 213-217
- https://doi.org/10.1016/0021-9150(93)90130-m
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100The Lancet, 1992
- Familial defective apolipoprotein B100: clinical characteristics of 54 casesAtherosclerosis, 1992
- Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100Atherosclerosis, 1991
- Poor response to simvastatin in familial defective apo-B-100The Lancet, 1991
- Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten casesAtherosclerosis, 1990
- A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group IIIPublished by American Medical Association (AMA) ,1988
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert PanelArchives of internal medicine (1960), 1988
- In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.Journal of Clinical Investigation, 1986
- Cholestyramine Promotes Receptor-Mediated Low-Density-Lipoprotein CatabolismNew England Journal of Medicine, 1980